Kong D, Roberts J, Lipman J, Taccone F, Cohen-Wolkowiez M, Sime F
Clin Pharmacokinet. 2024; 64(1):107-126.
PMID: 39722108
PMC: 11762590.
DOI: 10.1007/s40262-024-01460-6.
Venuti F, Gaviraghi A, De Nicolo A, Stroffolini G, Longo B, Di Vincenzo A
Antibiotics (Basel). 2023; 12(7).
PMID: 37508309
PMC: 10376517.
DOI: 10.3390/antibiotics12071214.
Narendrakumar L, Chakraborty M, Kumari S, Paul D, Das B
Front Microbiol. 2023; 13:1092556.
PMID: 36970185
PMC: 10036598.
DOI: 10.3389/fmicb.2022.1092556.
Soeorg H, Noortoots A, Karu M, Saks K, Lass J, Lutsar I
Eur J Clin Pharmacol. 2022; 78(6):989-1001.
PMID: 35275224
DOI: 10.1007/s00228-022-03307-0.
Chen N, Sun L, Hu W, Wang Y, Xie L, Cheng J
Front Pharmacol. 2020; 11:1033.
PMID: 32733255
PMC: 7360824.
DOI: 10.3389/fphar.2020.01033.
Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Simulation of Piperacillin/Tazobactam for Dosing Optimization in Late Elderly Patients with Pneumonia.
Ishihara N, Nishimura N, Ikawa K, Karino F, Miura K, Tamaki H
Antibiotics (Basel). 2020; 9(3).
PMID: 32155905
PMC: 7148462.
DOI: 10.3390/antibiotics9030113.
A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients.
Kalaria S, Gopalakrishnan M, Heil E
Antimicrob Agents Chemother. 2019; 64(3).
PMID: 31871076
PMC: 7038264.
DOI: 10.1128/AAC.02093-19.
Single-Center Investigation of the Pharmacokinetics of WCK 4282 (Cefepime-Tazobactam Combination) in Renal Impairment.
Preston R, Mamikonyan G, Mastim M, Garg D, Kemper C, Xu A
Antimicrob Agents Chemother. 2019; 63(10).
PMID: 31332068
PMC: 6761517.
DOI: 10.1128/AAC.00873-19.
The Quinazolinone Allosteric Inhibitor of PBP 2a Synergizes with Piperacillin and Tazobactam against Methicillin-Resistant Staphylococcus aureus.
Janardhanan J, Bouley R, Martinez-Caballero S, Peng Z, Batuecas-Mordillo M, Meisel J
Antimicrob Agents Chemother. 2019; 63(5).
PMID: 30858202
PMC: 6496080.
DOI: 10.1128/AAC.02637-18.
Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii.
Sakoulas G, Rose W, Berti A, Olson J, Munguia J, Nonejuie P
Antimicrob Agents Chemother. 2016; 61(2).
PMID: 27872080
PMC: 5278754.
DOI: 10.1128/AAC.01745-16.
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.
van Duin D, Bonomo R
Clin Infect Dis. 2016; 63(2):234-41.
PMID: 27098166
PMC: 4928383.
DOI: 10.1093/cid/ciw243.
Evaluation of efficacy and tolerability of cefotaxime and sulbactam versus cefepime and tazobactam in patients of urinary tract infection-a prospective comparative study.
Kaur K, Gupta A, Sharma A, Walia G, Singh B, Kaur K
J Clin Diagn Res. 2015; 8(11):HC05-8.
PMID: 25584242
PMC: 4290261.
DOI: 10.7860/JCDR/2014/9742.5090.
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Zhanel G, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F
Drugs. 2013; 74(1):31-51.
PMID: 24352909
DOI: 10.1007/s40265-013-0168-2.
Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.
Miller B, Hershberger E, Benziger D, Trinh M, Friedland I
Antimicrob Agents Chemother. 2012; 56(6):3086-91.
PMID: 22450972
PMC: 3370713.
DOI: 10.1128/AAC.06349-11.
Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.
Bulitta J, Kinzig M, Jakob V, Holzgrabe U, Sorgel F, Holford N
Br J Clin Pharmacol. 2010; 70(5):682-93.
PMID: 21039762
PMC: 2997308.
DOI: 10.1111/j.1365-2125.2010.03750.x.
Piperacillin-tazobactam penetration into human pancreatic juice.
Bertazzoni Minelli E, Benini A, Franco L, Bassi C, Pederzoli P
Antimicrob Agents Chemother. 2008; 52(11):4149-52.
PMID: 18809943
PMC: 2573103.
DOI: 10.1128/AAC.00509-08.
Penetration of piperacillin/tazobactam into gynecologic tissues following a single loading dose prior to hysterectomy.
OBrien W, George S
Infect Dis Obstet Gynecol. 1994; 2(1):20-4.
PMID: 18475361
PMC: 2364356.
DOI: 10.1155/S1064744994000347.
Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses.
Auclair B, Ducharme M
Antimicrob Agents Chemother. 1999; 43(6):1465-8.
PMID: 10348772
PMC: 89298.
DOI: 10.1128/AAC.43.6.1465.
Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.
Occhipinti D, Pendland S, Schoonover L, Rypins E, Danziger L, Rodvold K
Antimicrob Agents Chemother. 1997; 41(11):2511-7.
PMID: 9371358
PMC: 164153.
DOI: 10.1128/AAC.41.11.2511.
Assessment of biliary excretion of piperacillin-tazobactam in humans.
Westphal J, Brogard J, Caro-Sampara F, ADLOFF M, Blickle J, Monteil H
Antimicrob Agents Chemother. 1997; 41(8):1636-40.
PMID: 9257733
PMC: 163977.
DOI: 10.1128/AAC.41.8.1636.